Clinical Trails

A new early-phase clinical trial suggests that Enolen, a novel implant designed to deliver the prostate cancer drug enzalutamide directly into tumors, is both safe and practical for patients with early-stage disease. Researchers reported that no serious side effects above grade 3 were linked to either the implant procedure or the drug itself. Most patients […]

A phase 2 study shows that combining venetoclax and ibrutinib can produce strong and lasting responses in patients with marginal zone lymphoma, including those newly diagnosed and those whose disease has returned or resisted treatment. In the study of 14 patients, 79% responded to the treatment within 16 weeks, and 29% achieved a complete response.

A Phase 1 trial shows that trastuzumab rezetecan (SHR-A1811), a next-generation antibody-drug conjugate (ADC), is effective and well-tolerated in patients with HER2-expressing gastric (GC/GEJ) and colorectal cancers (CRC). Trastuzumab rezetecan works like a “smart bomb”: the HER2-targeting antibody directs the drug to cancer cells, while a linked chemotherapy payload is released inside tumors, limiting damage

A Phase 1 clinical trial suggests that adding the targeted drug VIC-1911 to standard care after donor stem cell transplants may greatly improve outcomes for patients with blood cancers. After a transplant, doctors must balance preventing graft-versus-host disease (GVHD), where donor immune cells attack the patient, while preserving the graft-versus-tumor effect that helps destroy cancer.

The Phase 3 SENTRY trial shows that adding selinexor (Xpovio) to ruxolitinib (Jakafi) improves outcomes for patients newly treated for myelofibrosis, especially in reducing spleen size. At 24 weeks, 50% of patients receiving the combination therapy achieved at least a 35% reduction in spleen volume, compared with 28% of those taking ruxolitinib alone. However, the

Researchers have developed a more advanced version of an oncolytic vaccinia virus, designed to safely target and kill cancer cells while sparing healthy tissue. Although this type of “living drug” has shown promise, earlier versions faced key challenges, including safety concerns from uncontrolled viral spread, risk of infecting others through skin lesions, and difficulty tracking

A Phase II clinical trial suggests that a medically supervised ketogenic diet (MSKD) may help improve outcomes for patients with metastatic pancreatic ductal adenocarcinoma receiving combination chemotherapy with gemcitabine, nab-paclitaxel, and cisplatin. The study included 32 evaluable patients and compared chemotherapy plus the ketogenic diet with chemotherapy plus a usual diet. Results showed encouraging trends

EnteroBiotix has completed patient enrollment for its Phase 2a MAST trial, testing the oral microbiome therapy EBX-102-02 in patients undergoing allogeneic stem cell transplants. The therapy is given as a single dose before chemotherapy to protect the gut microbiome, which is often damaged during transplant and linked to complications like Graft-vs-Host Disease (GVHD) and infections.

A phase 1 trial shows that a venetoclax-based transplant regimen is safe and effective for high-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia patients. The study focused on older patients with poor-risk features, including TP53 mutations, using a reduced-intensity conditioning of venetoclax with fludarabine and busulfan, followed by post-transplant maintenance with venetoclax and oral decitabine/cedazuridine. Results

The first part of the global ProstACT study has shown that the radiopharmaceutical TLX591-Tx (Lutetium-177 rosopatamab tetraxetan) is safe and tolerable when combined with standard therapies for advanced prostate cancer. The trial involved 36 patients with PSMA-positive metastatic castration-resistant prostate cancer who had already progressed on a first androgen receptor pathway inhibitor. Each patient received